Norsk
A word from the CEO
In 2017, we have seen a strong growth in the value of innovation and transformation of research into services and products that can benefit society.
The development of many of the companies we have helped to establish is more than satisfactory. At year-end, our total company portfolio was worth more than NOK 9 billion. This is a tripling of the total value in three years. In monetary terms, this growth in such a small space of time is substantial, but it also shows that the products developed on the basis of research at the University of Oslo and the hospitals in the South-Eastern Norway Regional Health Authority meet a need in society.
Read more
KEY FIGURES
205
NEW IDEAS
6
NEW COMPANIES ESTABLISHED
35
NEW LICENSE AGREEMENTS
83
NEW PATENT APPLICATIONS
160
NEW CLINICAL STUDIES
405
ONGOING CLINICAL STUDIES
9
BILLION NOK COMBINED VALUE OF PORTFOLIO COMPANIES
83
MILLION NOK TO
NEW RESEARCH
698
MILLION NOK IN PRIVATE CAPITAL RAISED
ABOUT INVEN2
Making a difference by transforming knowledge into products and services for the benefit of society.
Research and knowledge are the keys to addressing global challenges relating to health, climate and the environment. Highly capable researchers and clinicians from larger parts Norway report their ideas and discoveries to us. We develop and manage these ideas, and proceed with the ones that can be transformed into products that benefit society.
We have started businesses that develop better cancer therapies, combat antibiotic resistance and identify security breaches in complex IT systems. Two-thirds of our businesses and licences are in the field of life science, since the scientific community we represent is particularly strong in that field.
Another important area for us is to administer agreements on clinical trials on behalf of the hospitals in our region and in the northern part of Norway. We make active endeavours to get more international companies to carry out their clinical trials in Norway. That way, more innovative treatment can benefit more patients in Norway.
Inven2 is a limited company owned by the University of Oslo and Oslo University Hospital. Inven2 currently has 34 employees.
SUCCESS STORIES
2017 was an exciting year for Inven2 and the companies in our portfolio. See a selection of this year’s success stories.
Clinical trials are key to medical development
Clinical trials involve testing new drugs and medical equipment on human subjects. Clinical trials can be conducted on both healthy volunteers and patients.Clinical trials give health personnel important experience of new drugs and treatment methods, research experience and access to international networks.
Read moreEcosystem
Inven2 is part of a vital, ever-growing ecosystem in research and development.
In 2017, this community has been strengthened by the addition of the incubator ShareLab and Catapult Life Sciences.
Read more
Idéprisen 2017
Inven2’s annual idea competition where we award the best idea to a product or a service.
In 2017, we received 64 contributions. There were many good contributions, but the jury managed to select three finalists who were each rewarded NOK 25,000 to develop their idea. The finalists were ‘Min Pilot – en app for bedre samhandling om psykisk helse’ (‘My Pilot – an app for improved cooperation on mental health), ‘3D tool to plan and assist operations’ and ‘Targeted pharmacological treatment of ventricular arrhythmias’.
The three finalists were then launched on Facebook Polls, where the idea that received the most votes could win a further NOK 225,000, i.e. NOK 250,000 in total.
The winner of Idéprisen 2017 was the idea ‘Targeted pharmacological treatment of ventricular arrhythmias’.
Read more about the winner
CUTTING EDGE 2017
We are proud to co-organise the Cutting Edge Festival, Norway’s biggest science and technology event, where we present the latest in science, technology and innovation together with our partners Oslotech and the University of Oslo.
www.cuttingedgefestival.no Watch movie from Cutting EdgeCUTTING EDGE FESTIVALEN IN NUMBERS
1500
VISITORS
90
TALKES
9
Workshops
4
DEBATES
150
1-1 meetings
100
EXHIBITORS
Successful matchmaking at Cutting Edge
More than 150 meetings between researchers, mature companies and start-ups were held at this year’s matchmaking event at Cutting Edge.
Read morePORTFOLIO
The companies in our portfolio are worth almost NOK 9.2 billion and raised NOK 700 million in private capital in 2017.
cFIRE AS
Corall Studio AS
Dronebud AS
L-CK AS
Safenode AS
Smartlab Solutions AS
SporTech AS
STUDENT INNOVATION
Inven2 and StartUiO are working together to encourage entrepreneurships and business start-ups spun out of ideas from clever students. This has led to four new businesses being added to Inven2’s portfolio.
Read moreProducts
Inven2 want to make a difference by transforming research and knowledge into products and services for the benefit of society. We have contributed to the launching of many products and services. Here is a selection.
Reorganisation and major focus on digitalisation and e-health
Inven2 reorganised parts of its activities in 2017, and has now established digitalisation and e-health as a dedicated focus area. The purpose is to contribute to the development of more research-based products and services, especially in digital technology.
Do you have an idea that can be transformed into a product or service?
Then we would like to hear from you.
In brief, we have expertise and provide services relating to business development, patenting, communication, licensing, starting a business and obtaining funding. We also have a large network of partners in Norway and abroad.
Report inventionAt Inven2, you will meet highly competent employees who, in partnership with you, will:
- Carry out an assessment of your idea or discovery within two months.
- Draw up a commercial strategy for how the idea or discovery can be commercialised, based on a market analysis.
- Verify the idea or discovery. This is a demanding process that usually involves financing from the Research Council of Norway’s FORNY programme.
- Realise the idea or discovery. This is done either through licensing or as a business start-up.
- Once the business has been established, we help with business development.